Healthcare / Medical Instruments & SuppliesTaipei Exchange
$20.95
-0.33 (-1.58%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $45.0M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
22.5x
↑EV/EBITDA
8.6x
↓ROE
6.6%
↑Gross Margin
25.8%
↓Debt/Equity
0.42
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.8%
FCF CAGR
—
FCF margin
-11.7%
FCF / Net income
-1.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $779.0M · net income $54.2M · FCF $-91.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $779.0M | $779.0M | $744.2M | $734.1M | $677.0M |
| Net Income | $54.2M | $54.2M | $89.1M | $40.1M | $14.3M |
| EBITDA | $145.8M | $145.8M | $167.4M | $115.5M | $78.2M |
| EPS | — | — | 1.74 | 0.87 | 0.31 |
| Gross Margin | 25.8% | 25.8% | 32.0% | 27.3% | 19.9% |
| Operating Margin | 6.6% | 6.6% | 12.3% | 8.0% | 0.5% |
| Net Margin | 7.0% | 7.0% | 12.0% | 5.5% | 2.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.42 | 0.42 | 0.23 | 0.32 | 0.32 |
| Current Ratio | 1.71 | 1.71 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-91.3M | $-91.3M | $45.0M | $83.6M | $52.9M |
| Returns | |||||
| ROE | 6.6% | 6.6% | 11.1% | 6.0% | 2.2% |
| Valuation | |||||
| P/E | 22.53 | 22.53 | 16.67 | 19.71 | 49.61 |
| EV/EBITDA | 8.59 | 8.59 | 8.73 | 7.22 | 10.46 |
| P/B | 1.42 | 1.42 | 1.85 | 1.18 | 1.08 |
| Growth & Yield | |||||
| Revenue Growth | 4.7% | 4.7% | 1.4% | 8.4% | — |
| EPS Growth | — | — | 100.0% | 176.7% | — |
| Dividend Yield | 0.9% | 0.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.9%
Start / end P/E
n/dx → n/dx
EPS bridge
1.74 → n/d
Residual
-24.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.